Therefore, we hypothesized that TSPAN7 may affect the binding of PDL1 to PD1 in tumor cells by changing the morphology of tumor cells, and then affect the efficacy of anti-PDL1 immunotherapy. The gene discussed is TSPAN7; the disease is neoplasm.